GLP1R and diabetes mellitus: Currently, discovery of anti-diabetes drugs is limited to peptide agonists including GLP-1, extendin-4 and their analogs (Pabreja et al., 2014 ▸), while previously the development of small-molecule drugs to target this receptor was extremely challenging because of the lack of structural information about druggable small-molecule binding sites.